Evidence map›Paper›PMID 35708308›Full record

ArticleHuman vaccines & immunotherapeutics2022

Individual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study.

Masaki Machida, Hiroyuki Kikuchi, Takako Kojima, Itaru Nakamura, Reiko Saito, Tomoki Nakaya, Tomoya Hanibuchi, Tomoko Takamiya, Yuko Odagiri, Noritoshi Fukushima and 3 more

Abstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Social Cohesion and COVID-19: Integrative Review.Interactive journal of medical research · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Masaki MachidaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0002-7060-7305
Hiroyuki KikuchiDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0003-0510-1030
Takako KojimaDepartment of International Medical Communications, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0001-8300-2690
Itaru NakamuraDepartment of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.ORCID 0000-0001-8494-1278
Reiko SaitoDivision of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.ORCID 0000-0002-1554-8226
Tomoki NakayaGraduate School of Environmental Studies, Tohoku University, Sendai, Japan.ORCID 0000-0002-3827-1012
Tomoya HanibuchiGraduate School of Environmental Studies, Tohoku University, Sendai, Japan.ORCID 0000-0002-0447-7645
Tomoko TakamiyaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0003-0821-9675
Yuko OdagiriDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0002-7603-4800
Noritoshi FukushimaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0003-1819-554X
Shiho AmagasaDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0002-6047-0771
Hidehiro WatanabeDepartment of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.ORCID 0000-0002-1835-9543
Shigeru InoueDepartment of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan.ORCID 0000-0003-1931-2613

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To reduce vaccine hesitancy, it is important to identify factors that can intervene at the individual or community level. Social capital is a possible factor because it is associated with various vaccine hesitancy, such as for measles and influenza. However, limited studies have explored the association between social capital and vaccination for COVID-19, which is an unprecedented pandemic and infodemic. Therefore, this study aimed to clarify the association between social capital and COVID-19 vaccination during the pandemic. This cross-sectional study used quota sampling for an online-based survey. Participants were asked whether they had previously been vaccinated for COVID-19 and their intention to receive a COVID-19 vaccine booster. Social capital was evaluated using three measures (individual-level civic participation, social cohesion, and reciprocity). Multiple logistic regression analysis was performed to clarify the association between social capital and previous COVID-19 vaccination status as well as intention to receive a COVID-19 booster. Participants were 2,313 individuals, of whom 87.2% had received a COVID-19 vaccine; 72.3% intended to obtain a COVID-19 booster. Individuals with any social capital are more likely to receive a COVID-19 vaccination than those with none (OR: 1.73, 95%CI: 1.18-2.54; OR: 1.58, 95%CI: 1.22-2.05; OR: 3.05, 95%CI: 2.15-4.33). These indicators were also associated with the intention to receive a COVID-19 booster. Thus, our results suggest that among the general public, those with individual-level social capital are more likely to receive a COVID-19 vaccination than those with none. Social capital may be a factor that can reduce vaccine hesitancy during a pandemic.

Indexed as

COVID-19Social CapitalCOVID-19 VaccinesCross-Sectional StudiesHumansImmunization, SecondaryJapanVaccinationVaccination HesitancyCOVID-19 VaccinesCoronavirus diseasemessenger RNA vaccinesocial capitalvaccine acceptancevaccine hesitancy

Identifiers

PMID35708308
PMCPMC9621029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.